静脉注射酮咯酸在新生儿和早产儿中的应用。
Use of intravenous ketorolac in the neonate and premature babies.
作者信息
Papacci Patrizia, De Francisci Giovanni, Iacobucci Tiziana, Giannantonio Carmen, De Carolis Maria Pia, Zecca Enrico, Romagnoli Costantino
机构信息
Department of Paediatrics, Division of Neonatology, Catholic University Sacred Heart, Rome, Italy.
出版信息
Paediatr Anaesth. 2004 Jun;14(6):487-92. doi: 10.1111/j.1460-9592.2004.01250.x.
BACKGROUND
Ketorolac is a powerful nonsteroidal anti-inflammatory drug widely used for pain control in children and adults. The aim of this study was to evaluate its safety and analgesic efficacy in the neonate.
METHODS
Ketorolac was used in a group of 18 spontaneously breathing neonates presenting with chronic lung disease, for the control of postsurgical pain and pain from invasive procedures. Pain scores (Neonatal Infant Pain Scale) were assessed before and after i.v. administration of 1 mg.kg(-1) of ketorolac.
RESULTS
Total pain control was achieved in 94.4% of the neonates. None of the neonates had haematological, renal or hepatic changes prior to treatment, and these complications did not occur after treatment. No neonate had systemic haemorrhage or bleeding from injection and blood withdrawal sites.
CONCLUSIONS
Ketorolac could represent an efficacious analgesic alternative to opioids, particularly in neonates. It would avoid the side-effects associated with opioid analgesics, especially respiratory depression.
背景
酮咯酸是一种强效非甾体抗炎药，广泛用于儿童和成人的疼痛控制。本研究的目的是评估其在新生儿中的安全性和镇痛效果。
方法
对一组18例患有慢性肺病的自主呼吸新生儿使用酮咯酸，用于控制术后疼痛和侵入性操作引起的疼痛。在静脉注射1mg·kg⁻¹酮咯酸前后评估疼痛评分（新生儿婴儿疼痛量表）。
结果
94.4%的新生儿实现了完全疼痛控制。治疗前所有新生儿均无血液学、肾脏或肝脏变化，治疗后也未出现这些并发症。没有新生儿出现全身性出血或注射及采血部位出血。
结论
酮咯酸可能是阿片类药物有效的镇痛替代品，尤其是在新生儿中。它可避免与阿片类镇痛药相关的副作用，尤其是呼吸抑制。
Zotero 插件